 Connection
Paul Bunn to Drug Evaluation
This is a "connection" page, showing publications Paul Bunn has written about Drug Evaluation.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.137 |
|
|
|
-
Roenigk HH, Kuzel TM, Skoutelis AP, Springer E, Yu G, Caro W, Gilyon K, Variakojis D, Kaul K, Bunn PA, et al. Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma. J Invest Dermatol. 1990 Dec; 95(6 Suppl):198S-205S.
Score: 0.022
-
Kaplan EH, Rosen ST, Norris DB, Roenigk HH, Saks SR, Bunn PA. Phase II study of recombinant human interferon gamma for treatment of cutaneous T-cell lymphoma. J Natl Cancer Inst. 1990 Feb 07; 82(3):208-12.
Score: 0.021
-
Foon KA, Roth MS, Bunn PA. Interferon therapy of non-Hodgkin's lymphoma. Cancer. 1987 Feb 01; 59(3 Suppl):601-4.
Score: 0.017
-
Bunn PA, Ihde DC, Foon KA. The role of recombinant interferon alfa-2a in the therapy of cutaneous T-cell lymphomas. Cancer. 1986 Apr 15; 57(8 Suppl):1689-95.
Score: 0.016
-
Bunn PA, Foon KA, Ihde DC, Longo DL, Eddy J, Winkler CF, Veach SR, Zeffren J, Sherwin S, Oldham R. Recombinant leukocyte A interferon: an active agent in advanced cutaneous T-cell lymphomas. Ann Intern Med. 1984 Oct; 101(4):484-7.
Score: 0.014
-
Bunn PA, Nugent JL, Ihde DC, Cohen MH, Eddy JL, Minna JD. 5-fluorouracil, methyl-CCNU, adriamycin, and mitomycin C in the treatment of advanced gastric cancer. Cancer Treat Rep. 1978 Sep; 62(9):1287-93.
Score: 0.009
-
Taylor CW, Chase EM, Whitehead RP, Rinehart JJ, Neidhart JA, Gonzalez R, Bunn PA, Hersh EM. A Southwest Oncology Group Phase I study of the sequential combination of recombinant interferon-gamma and recombinant interleukin-2 in patients with cancer. J Immunother (1991). 1992 Apr; 11(3):176-83.
Score: 0.006
-
Kuzel TM, Gilyon K, Springer E, Variakojis D, Kaul K, Bunn PA, Evans L, Roenigk HH, Rosen ST. Interferon alfa-2a combined with phototherapy in the treatment of cutaneous T-cell lymphoma. J Natl Cancer Inst. 1990 Feb 07; 82(3):203-7.
Score: 0.005
-
Kohn EC, Steis RG, Sausville EA, Veach SR, Stocker JL, Phelps R, Franco S, Longo DL, Bunn PA, Ihde DC. Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the S?zary syndrome. J Clin Oncol. 1990 Jan; 8(1):155-60.
Score: 0.005
-
Carrasquillo JA, Mulshine JL, Bunn PA, Reynolds JC, Foon KA, Schroff RW, Perentesis P, Steis RG, Keenan AM, Horowitz M, et al. Indium-111 T101 monoclonal antibody is superior to iodine-131 T101 in imaging of cutaneous T-cell lymphoma. J Nucl Med. 1987 Mar; 28(3):281-7.
Score: 0.004
-
Batist G, Carney DN, Cowan KH, Veach SR, Gilliom M, Bunn PA, Ihde DC. Etoposide (VP-16) and cisplatin in previously treated small-cell lung cancer: clinical trial and in vitro correlates. J Clin Oncol. 1986 Jun; 4(6):982-6.
Score: 0.004
-
Morstyn G, Ihde DC, Eddy JL, Bunn PA, Cohen MH, Minna JD. Combination chemotherapy of hepatocellular carcinoma with doxorubicin and streptozotocin. Am J Clin Oncol. 1983 Oct; 6(5):547-51.
Score: 0.003
-
Krasnow S, Bunn PA, Ihde DC, Matthews MJ, Cohen MH, Eddy J, Minna JD. ICRF-159 in advanced gastric cancer. Absence of activity. Am J Clin Oncol. 1982 Dec; 5(6):635-9.
Score: 0.003
-
Levenson RM, Ihde DC, Huberman MS, Cohen MH, Bunn PA, Minna JD. Phase II trial of cisplatin in small cell carcinoma of the lung. Cancer Treat Rep. 1981 Sep-Oct; 65(9-10):905-7.
Score: 0.003
-
Radice PA, Bunn PA, Ihde DC. Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies. Cancer Treat Rep. 1979 Aug; 63(8):1231-9.
Score: 0.003
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|